Quantcast

Cleveland BioLabs Granted First Patent for Protectan CBLB502

July 8, 2008

Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced today that its first patent for Protectan CBLB502 was granted by the Eurasian Patent Organization (EAPO), which includes nine member countries. This patent covers the method of protecting a mammal from radiation using flagellin or its derivatives, including Protectan CBLB502.

Cleveland BioLabs has filed over twenty patent applications in the U.S. and internationally, around various properties of Protectan CBLB502 and related compounds, including methods of use and composition of matter. Yakov Kogan, Ph.D., MBA, Chief Operating Officer of Cleveland BioLabs, noted that the EAPO patent was the first of several expected approvals. “We have been progressing well with patent examination in various geographies and we hope to receive the first of our U.S. patents related to method of use for Protectan CBLB502 in the coming months.”

Protectan CBLB502 is a derivative of a microbial protein that reduces injury from acute stresses, such as radiation and chemotherapy, by mobilizing several natural cell protecting mechanisms, including inhibition of programmed cell death (apoptosis), reduction of oxidative damage and induction of regeneration promoting cytokines.

Cleveland BioLabs received a contract from the Department of Defense valued at up to $8.9 million for the advanced development of Protectan CBLB502 as a medical radiation countermeasure to treat radiation injury following exposure to radiation from nuclear or radiological weapons. Protectan CBLB502 is undergoing expedited approval for this use through the FDA’s two-animal rule requiring efficacy in animals and safety testing in a representative sample of healthy human volunteers. Protectan CBLB502 has demonstrated efficacy in multiple animal species including non-human primates and is expected to start human safety studies in 2008. A Phase I/II medical trial for Protectan CBLB502 in head and neck cancer patients for reduction of radiation and chemotherapy toxicities is also expected to start later in 2008.

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs, Inc., please visit the company’s website at http://www.cbiolabs.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Some of the factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s periodic filings with the Securities and Exchange Commission.

 Contact: Rachel Levine Director Corporate Development & Communications Cleveland BioLabs, Inc. T: (646) 284-9439 E: rlevine@cbiolabs.com

SOURCE: Cleveland BioLabs, Inc.




comments powered by Disqus